Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Q&A Session from Webinar with Dr. Lilenbaum on Managing Elderly Patients with Lung Cancer
Dr West
Author
Howard (Jack) West, MD

Following the excellent podcast by Dr. Rogerio Lilenbaum, lung cancer expert and now Chair of Cleveland Clinic Florida in Weston, on Considerations and Challenges of Treating Elderly Patients with Lung Cancer, he fielded questions from me and the folks in the live audience who attended. Here's that question and answer session, provided in audio and with the associated transcript. There isn't really any video/figures for this one.

[powerpress]

dr-lilenbaum-qa-on-treating-lung-cancer-in-elderly-pts-transcript

As always, thanks very much to LUNGevity Foundation for working with GRACE to make the webinar and podcast possible.

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

Recent Comments

JOIN THE CONVERSATION
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on